Comparison between Intermittent Bolus versus Continuous Intravenous Infusion of Tranexamic Acid in Haematological Disorders with Thrombocytopenia - BRAVE

CMC Ludhiana0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Subjects will be eligible for the trial if they have a confirmed diagnosis of one of the following hematological disorders and with a platelet count below 20000/cumm and those who are willing to give consent.
•1.Acute myeloid leukemia
•2.Acute lymphoblastic leukemia
•3.Aplastic anemia
•4.Immune thrombocytopenia

•1. Patients with a previous history or current diagnosis of arterial or venous thromboembolic disease, including myocardial infarction, peripheral vascular disease and retinal arterial or venous thrombosis;
•2. Diagnosis of acute promyelocytic leukemia and undergoing induction chemotherapy
•3. Diagnosis/history of veno-occlusive disease (VOD) (also called
•sinusoidal obstruction syndrome)
•4. Known inherited or acquired prothrombotic disorders.
•5. Thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome
•6. Overt disseminated intravascular coagulation
•7. Known inherited or acquired bleeding disorder, such as acquired storage pool deficiency
•8. Paraproteinaemia with platelet inhibition receiving anti-coagulant therapy or antiplatelet therapy
•9. Visible haematuria at time of randomisation
•10. Anuria (defined as urine output of less than 10 mL/h over 24 h)
•11. Severe renal impairment (estimated glomerular filtration rate of not more than 30 mL/min per 1.73 m2)
•12. History of epilepsy, convulsions, fits or seizures
•13. Pregnant or breast-feeding
•14. Allergic to TXA, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents.

发起方

CMC Ludhiana